Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective post-marketing surveillance of RECTABUL 2 mg rectal formulation (budesonide) in ulcerative colitis
jRCT1080223802Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of budesonide in autoimmune colitis, sponsored by EA Pharma Co., Ltd. Started Feb 2018; status: completed.
02
Drugs
budesonide
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT1080223802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223802.